New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
11:34 EDTVIVOMeridian receives Canadian licenses for two illumigene platforms
Meridian Bioscience announced that it has received medical device license approval from Health Canada to market two additional assays for use on their illumigene molecular diagnostic platform. With the addition of illumigene Mycoplasma and illumigene Pertussis, Meridian continues to expand its position in the Canadian market by providing innovative testing solutions that meet the needs of the clinical laboratory and drive improvements in patient care.
News For VIVO From The Last 14 Days
Check below for free stories on VIVO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 3, 2014
07:31 EDTVIVOMeridian Bioscience signs agreement with Premier to offer illumigene tests
Subscribe for More Information
September 2, 2014
07:39 EDTVIVOMeridian Bioscience sees 'modest' revenue and profit growth in FY15
John A. Kraeutler, CEO, stated, “Our revenue guidance range of $193M-$200M for FY15 is based upon expectations that the markets we target will continue to be highly competitive as established and new diagnostics competitors attempt to advance their new molecular platforms. For our Life Science units, double-digit growth should continue for our Bioline molecular components business, somewhat offset by lower growth rates in our core immunoassay components business." William J. Motto, Executive Chairman, commented, “The outlook for FY15 is for modest revenue and profit growth. In the upcoming year we intend to accelerate our search for new growth opportunities. Of course, we will continue to drive efficient operations, introduce new products, and maintain our strong balance sheet. Management will be recommending to the Board of Directors that the current indicated annual dividend rate of 80c be maintained.”
07:37 EDTVIVOMeridian Bioscience reaffirms FY14 EPS view 85c-90c, consensus 86c
Subscribe for More Information
07:37 EDTVIVOMeridian Bioscience sees FY15 EPS 85c-91c, consensus 97c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use